Overview

* Passage Bio ( PASG ) Q3 net loss narrows to $7.7 mln from $19.3 mln yr/yr

* Cash position decreased to $52.8 mln, funding operations into Q1 2027

Outlook

* Passage Bio's ( PASG ) cash runway extends into 1Q 2027

Result Drivers

* R&D expenses were $4.3 million for the quarter ended September 30, 2025, as compared to $8.7 million for the quarter ended September 30, 2024.

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$7.75

Income mln

Q3 -$8.66

Income mln

From

Operatio

ns

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Passage Bio Inc ( PASG ) is $53.50, about 88.3% above its November 7 closing price of $6.29

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)